Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Evommune, Inc.NYSE: EVMN
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 747.1% from a year ago
Cash & equivalents stood at $48.32M at the end of Q1 FY2026, up 747.1% from a year earlier and up 9.7% from the prior quarter.
Context
- Cash & equivalents amounted to 15.0% of total assets at the end of Q1 FY2026, up 4.8 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +747.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 44.06M USD
- Year-over-year change
- +171.1%
- 2-year CAGR
- +23.2%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 44.06M | +171.1% |
| FY2024 | 2024-12-31 | 16.25M | -44.0% |
| FY2023 | 2023-12-31 | 29.02M | — |
Cash & Equivalents vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's Mar 2026 cash & equivalents of $48.32M is the 6th highest of the 10 companies compared; the peer median is $77.71M.
- Its year-over-year change of +747.1% is the 2nd highest of 10, against a peer median of +102.0%.
- Cash & equivalents amounts to 15.0% of total assets for EVMN, versus a peer median of 19.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.01B | +1387.7% | +57.2% | 46.1% | |
FTREFortrea Holdings Inc. | Jun 2026 | $168.6M | +107.6% | +16.0% | 6.2% |
| Sep 2026 | $100.46M | +55.0% | -53.2% | 8.5% | |
| Mar 2026 | $90.85M | +134.3% | -23.5% | 69.1% | |
| Mar 2026 | $77.71M | -8.7% | +2.1% | 27.0% | |
EVMNEvommune, Inc. | Mar 2026 | $48.32M | +747.1% | — | 15.0% |
| Mar 2026 | $37M | +102.0% | -23.6% | 28.6% | |
| Mar 2026 | $29.05M | +166.7% | -8.6% | 9.9% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $20.96M | -31.1% | -36.1% | 19.8% |
CLYMClimb Bio, Inc. | Mar 2026 | $8.36M | -71.2% | -6.4% | 5.5% |
| Peer median (excluding EVMN) | $77.71M | +102.0% | -8.6% | 19.8% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.